Samsung Biologics revenue and financials
₩1,277,000.00Change from previous close: −2.52%Absolute change: −₩33,000.00
In the fiscal year ended December 2025, Samsung Biologics reported revenue of ₩4.56T (+30.31% year over year). Net income was ₩1.78T, a net margin of 39.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +30.31%
- 2025 vs 2024
- Net income growth
- +64.71%
- 2025 vs 2024
- Net margin
- 39.2%
- 2024: 31.0%
Financial data
Amounts in millions of KRW; per-share values in KRW; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 1,320,911 | 1,257,119 | 1,286,000 | 1,660,221 | 1,014,238 | 999,545 | — | 1,187,075 | 1,156,904 | 946,903 | 1,073,509 | 1,033,973 |
| Cost of revenue | 622,579 | 578,274 | 614,000 | 685,412 | 450,791 | 461,152 | — | 646,205 | 501,783 | 528,557 | 544,989 | 534,019 |
| Gross profit | 698,332 | 678,846 | 672,000 | 974,808 | 563,446 | 538,392 | — | 540,870 | 655,121 | 418,346 | 528,520 | 499,955 |
| Selling, general and administrative | 87,897 | 81,679 | 144,000 | 198,012 | 69,212 | 88,051 | — | 163,336 | 172,493 | 160,930 | 133,951 | 140,226 |
| Research and development | 9,032 | 7,238 | -72,698 | 34,281 | 8,634 | 7,582 | — | 29,617 | 26,581 | 24,575 | 22,402 | 21,115 |
| Operating income | 586,444 | 580,753 | 528,000 | 728,848 | 477,202 | 430,240 | — | 338,578 | 434,511 | 221,299 | 349,968 | 318,531 |
| EBIT | 586,444 | 580,753 | 528,000 | 728,848 | 477,202 | 430,240 | — | 338,578 | 434,511 | 221,299 | 349,968 | 318,531 |
| EBITDA | 698,522 | 675,311 | 556,741 | 907,768 | 655,399 | 593,640 | — | 495,400 | 582,557 | 364,716 | 491,913 | 457,056 |
| Interest expense | 8,776 | 7,146 | 285 | 10,707 | 5,157 | 7,394 | — | 1,725 | 8,175 | 16,087 | 19,470 | 21,640 |
| Pre-tax income | 584,629 | 640,593 | 575,000 | 767,004 | 442,365 | 439,102 | — | 290,999 | 464,960 | 240,077 | 355,712 | 316,313 |
| Income tax | 153,975 | 171,348 | 122,000 | 192,544 | 108,796 | 107,769 | — | 26,531 | 146,968 | 60,715 | 65,028 | 75,946 |
| Net income | 430,654 | 469,245 | 510,000 | 574,460 | 324,386 | 375,554 | — | 264,468 | 317,992 | 179,362 | 290,684 | 240,367 |
| Net income to common shareholders | 430,654 | 469,245 | 510,000 | 574,460 | 324,386 | 375,554 | — | 264,468 | 317,992 | 179,362 | 290,684 | 240,367 |
| Basic EPS | 9,313.55 | 10,148.15 | 14,382.79 | 12,409.76 | 7,007.55 | 8,112.89 | — | 5,713.18 | 6,869.42 | 3,874.66 | 6,279.49 | 5,192.52 |
| Diluted EPS | 9,313.55 | 10,148.00 | 14,382.79 | 12,409.45 | 7,007.55 | 8,112.50 | — | 5,713.18 | 6,869.42 | 3,874.59 | 6,279.30 | 5,192.26 |
| Average shares (basic) | 46.2 | 46.2 | 35.5 | 46.3 | 46.3 | 46.3 | — | 46.3 | 46.3 | 46.3 | 46.3 | 46.3 |
| Average shares (diluted) | 46.2 | 46.2 | 35.5 | 46.3 | 46.3 | 46.3 | — | 46.3 | 46.3 | 46.3 | 46.3 | 46.3 |